Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.

April 11, 2017 updated by: Mikkel Bring Christensen

An Investigation Into the Effects of Intravenous Lipid Emulsion (ILE) on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.

The aim of this study is to investigate whether intravenous lipid emulsion is effective in attenuating the clinical effects of a cardioactive drug, exemplified by the beta-blocking agent metoprolol. In addition, the investigators will clarify how intravenous lipid emulsion affects the pharmacokinetic parameters of metoprolol.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Overdose or poisonings with cardioactive drugs can have serious consequences. In recent years, intravenous lipid emulsion has emerged as a possible treatment option in otherwise treatment-resistant cardiovascular collapse caused by poisonings with cardio-active drugs.

Experimental evidence obtained from animal studies has been indicating a beneficial effect of intravenous lipid emulsion in the treatment of poisoning with various cardio-toxic medications. Based on these findings, the first reported cases on the use of intravenous lipid emulsion in the treatment of human cardiotoxicity caused by poisonings with local anesthetics were published in 2006. Subsequently, a steadily increasing number of case reports concerning the use of intravenous lipid emulsion in resuscitation and treatment of various medications poisonings have been published. Often patients had either cardiac arrest or severe circulatory failure treated according to guidelines for advanced life support prior to lipid emulsion therapy. It is noteworthy that a common observation following bolus infusion of lipid emulsion has been a rapid hemodynamic stabilization of the patient.

Despite an increasing use of intravenous lipid emulsion in the treatment of the poisoned patient, the mechanism behind lipid rescue has not been elucidated. The most widely accepted hypothesis, the "lipid sink/sponge" model, suggests that intravenous lipid emulsion entraps xenobiotics intravascularly, thereby preventing them from reaching sites of toxicity. Additionally, intravenous lipid emulsion may redistribute xenobiotics to areas of higher lipid content. However, other mechanisms of actions of lipid emulsion, supported by observations from animal experiments, are vasoconstrictive and cardio-tonic effects. These effects could be secondary to direct activation of sodium, potassium or calcium channels in the myocardium, or alternatively fatty acid-induced modulation of the metabolic properties of mitochondria. Both mechanisms could result in hemodynamic stabilization. The potential beneficial effects of lipid emulsion on hemodynamic instability beyond the lipid sink have led to the notion that intravenous lipid emulsion could be valuable in the treatment of poisonings with non-lipophilic xenobiotics.

At present, it remains however unclear to what extent the evidence concerning resuscitation of the poisoned patient with lipid emulsion may reflect publication bias. To our knowledge, only one controlled human trial has been conducted at present. In a randomized crossover study, Litonius et al. investigated the effects of lipid emulsion on plasma concentrations of bupivacaine in eight healthy subjects. It was found that lipid emulsion lowered the total plasma concentrations of bupivacaine. This was attributed to an altered distribution and contradicted so the above hypothesis of a lipid sink-mechanism as the fraction of non-lipid bound bupivacaine was unchanged. The mechanism by which lipid emulsion may attenuate the effects of cardio toxic xenobiotics must therefore still be regarded as undecided. This lack of evidence calls for further human studies in order to elucidate the pharmacokinetic and pharmacodynamic consequences of intravenous lipid emulsion. The purpose of this double blind, randomized placebo-controlled crossover clinical trial is to investigate the effects of intravenous lipid emulsion on the pharmacokinetic and pharmacodynamic properties of the adrenoceptor antagonist metoprolol in a human model of beta blocker overdose.

The study includes a total of five visits; a screening visit and four trial days. At the screening visit, anthropometric data (weight, height, blood pressure and pulse) is measured. Additionally, blood samples are collected in accordance with exclusion criteria. A spot urine sample measuring the albumin/creatinine ratio is collected and an electrocardiogram (ECG) is recorded to verify normality of heart rhythm and electrical impulses. In addition, an investigator carries out a clinical examination. Based on the clinical examination, urine and blood tests and ECG measurement, the investigator assesses whether the trial participant meet all inclusion criteria and no exclusion criteria.

After screening and inclusion, participants will be invited to four trial days at the trial site. On each day participants are required to be fasting for 10 hours (including water, coffee and tobacco). A peripheral venous line is inserted into each antecubital vein. An arterial catheter connected to a pressure transducer is inserted into the radial artery in the wrist. In randomized order, one of the four interventions are performed (see below). A standard 12 lead ECG is placed on the participant as well as a 5 lead ECG connected to a computer.

At T=0, metoprolol intravenous solution (0.5 mg metoprolol/ml as metoprolol tartrate) or placebo is administered as an intravenous bolus injection. Continuous infusion of metoprolol/placebo is then administered until T=30 minutes. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes. Intravenous lipid emulsion (Intralipid 20 %) or saline solution is shortly thereafter administered as an intravenous bolus infusion (1.5 ml/kg) followed by a continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion/dummy infusion is stopped at T = 30 minutes. One gram of paracetamol administered as a disintegrating tablet dissolved in 50 ml of water is given per os shortly before study start on each day.

Repeated ECG's are recorded and blood is drawn for measurements of routine biochemistry parameters and serum concentrations of metoprolol and paracetamol. A drop of blood is used to test glucose levels using a blood glucose meter. Cardiovascular parameters (heart rate, blood pressure, pulse contour curve/arterial pressure wave) are recorded via the arterial catheter and pressure transducer connected to a computer. The participant is closely monitored on site until T=120 minutes.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
    • Capital Region of Denmark
      • Copenhagen NW, Capital Region of Denmark, Denmark, 2400
        • Bispebjerg University Hospital Copenhagen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 30 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

- healthy male.

Exclusion Criteria:

  • Abnormal blood levels of sodium, potassium, creatinine, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, albumin, bilirubin, hemoglobin, HbA1c, cholesterol fractions.
  • Abnormal urine albumin to creatinine ratio.
  • Abnormal function of CYP2D6 metabolism (ultrarapid or slow metabolizer)
  • Any heart disease or hypertension
  • Sinoatrial block
  • Second or third degree atrioventricular block
  • Heart failure
  • profound bradycardia or hypotension
  • sinoatrial node disease
  • metabolic acidosis
  • untreated pheochromocytoma
  • asthma
  • chronic obstructive pulmonary disease
  • intermittent claudicatio
  • diabetes
  • Allergy to egg, soy or peanut protein and allergy to any active or inactive ingredients contained in metoprolol (Seloken) or the lipid emulsion (Intralipid)
  • Raynaud's syndrome
  • Prinzmetal's angina

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Metoprolol-Lipid emulsion
intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
Drug: metoprolol
One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
Other Names:
  • metoprolol tartrate
  • Seloken
  • ATC: C07AB02
Drug: intravenous lipid emulsion
Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
Other Names:
  • Intralipid
  • ATC: B05BA02
Experimental: Metoprolol - normal saline
intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
Drug: metoprolol
One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
Other Names:
  • metoprolol tartrate
  • Seloken
  • ATC: C07AB02
Drug: Sodium chloride 0.9% solution - lipid emulsion dummy
Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
Other Names:
  • Normal saline
Experimental: Normal saline-Lipid emulsion
intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
Drug: intravenous lipid emulsion
Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
Other Names:
  • Intralipid
  • ATC: B05BA02
Drug: Sodium chloride 0.9% solution - metoprolol dummy
Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
Other Names:
  • Normal saline
Experimental: Normal saline-normal saline
intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
Drug: Sodium chloride 0.9% solution - lipid emulsion dummy
Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
Other Names:
  • Normal saline
Drug: Sodium chloride 0.9% solution - metoprolol dummy
Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
Other Names:
  • Normal saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in heart rate from baseline compared between study days
Time Frame: From baseline to + 120 minutes.
Arterial catheter connected to a pressure transducer records heart rate (beats per minute).
From baseline to + 120 minutes.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area under the plasma concentration versus time curve (AUC) of metoprolol on days with co-administration of intravenous lipid emulsion compared to days with lipid emulsion placebo.
Time Frame: 0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Blood samples drawn from an antecubital vein.
0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Peak plasma concentration (Cmax) of paracetamol on days with co-administration of intravenous lipid emulsion compared to days with lipid emulsion placebo.
Time Frame: 0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Paracetamol is used as a tool for measuring gastric emptying time.
0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Area under the plasma concentration versus time curve (AUC) of paracetamol on days with co-administration of intravenous lipid emulsion compared to days with lipid emulsion placebo.
Time Frame: 0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Paracetamol is used as a tool for measuring gastric emptying time.
0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Time to peak plasma concentration (Tmax) of paracetamol on days with co-administration of intravenous lipid emulsion compared to days with lipid emulsion placebo.
Time Frame: 0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Paracetamol is used as a tool for measuring gastric emptying time.
0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Percent change in plasma levels of standard biochemical measurements from baseline compared between study days.
Time Frame: Changes at +30 and +60 minutes from baseline.
Blood samples drawn from an antecubital vein measuring alanine aminotransferase, aspartate aminotransferase, albumin, bilirubin, alkaline phosphatase, calcium, creatine kinase, creatinine, C-reactive protein, high density lipoprotein, potassium, sodium, glucagon, lactate dehydrogenase, haptoglobin, triglycerides, and whole blood glucose levels(measured with a glucose meter).
Changes at +30 and +60 minutes from baseline.
Peak Plasma Concentration (Cmax) of metoprolol on days with co-administration of intravenous lipid emulsion compared to days with lipid emulsion placebo.
Time Frame: +0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Blood samples drawn from an antecubital vein measuring plasma metoprolol.
+0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Time to peak plasma concentration (Tmax) of metoprolol on days with co-administration of intravenous lipid emulsion compared to days with lipid emulsion placebo.
Time Frame: +0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Blood samples drawn from an antecubital vein measuring plasma metoprolol.
+0, +10, +20, +30, +40, +50, +60, +90, +120 minutes post metoprolol dose.
Cardiac conductivity between days with metoprolol and/or intravenous lipid emulsion compared with placebo.
Time Frame: T-10, T-5, T 0, T 10, T 20, T 30, T 40, T 50, T 60, T 90, T 120 minutes.
12-lead ECG
T-10, T-5, T 0, T 10, T 20, T 30, T 40, T 50, T 60, T 90, T 120 minutes.
Effects of metoprolol and lipid emulsion on stroke volume compared to days with placebo.
Time Frame: T-10, T-5, T 0, T 10, T 20, T 30, T 40, T 50, T 60, T 90, T 120 minutes.
Stroke volume (mL) derived from arterial pulse contour analysis.
T-10, T-5, T 0, T 10, T 20, T 30, T 40, T 50, T 60, T 90, T 120 minutes.
Effect of metoprolol on systolic, diastolic and mean arterial pressure on days with co-administration of intravenous lipid emulsion compared to days with placebo.
Time Frame: T-10, T-5, T 0, T 10, T 15, T 20, T 30, T 40, T 50, T 60, T 90, T100, T110, T 120 minutes.
Arterial catheter connected to a pressure transducer records blood pressure in mm Hg.
T-10, T-5, T 0, T 10, T 15, T 20, T 30, T 40, T 50, T 60, T 90, T100, T110, T 120 minutes.
Change in systolic, diastolic and mean arterial pressure from baseline compared between study days.
Time Frame: Changes at +5, +10, +15, +20, +30, +40, +50, +60, +90, +95, +100, +105, +110, +115, +120 minutes from baseline.
Arterial catheter connected to a pressure transducer records blood pressure in mm Hg.
Changes at +5, +10, +15, +20, +30, +40, +50, +60, +90, +95, +100, +105, +110, +115, +120 minutes from baseline.
Change in heart rate from baseline compared between study days.
Time Frame: Changes at +5, +10, +15, +20, +30, +40, +50, +60, +90, +95, +100, +105, +110, +115, +120 minutes from baseline.
Arterial catheter connected to a pressure transducer records heart rate (beats per minute).
Changes at +5, +10, +15, +20, +30, +40, +50, +60, +90, +95, +100, +105, +110, +115, +120 minutes from baseline.
Change in stroke volume (ml) from baseline compared between study days.
Time Frame: Changes at +5, +10, +15, +20, +30, +40, +50, +60, +90, +95, +100, +105, +110, +115, +120 minutes from baseline.
Stroke volume (ml) derived from arterial pulse contour analysis.
Changes at +5, +10, +15, +20, +30, +40, +50, +60, +90, +95, +100, +105, +110, +115, +120 minutes from baseline.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mikkel Bring Christensen

Investigators

  • Principal Investigator: Mikkel B Christensen, MD, PhD, Bispebjerg University Hospital, Copenhagen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2016

Primary Completion (Actual)

March 10, 2017

Study Completion (Actual)

March 10, 2017

Study Registration Dates

First Submitted

September 6, 2016

First Submitted That Met QC Criteria

October 3, 2016

First Posted (Estimate)

October 5, 2016

Study Record Updates

Last Update Posted (Actual)

April 12, 2017

Last Update Submitted That Met QC Criteria

April 11, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Intralipid-Metoprolol

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe